FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
WATERTOWN, Mass., Feb. 19, 2016 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will report fourth quarter and full year financial results after the close of U.S. financial markets on February 23, 2016, and will host a conference call on Tuesday, February 23 at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
The call can be accessed by dialing (844) 831-4023 (U.S. and Canada) or (731) 256-5215 (international) and entering passcode 55430612. To access the live audio webcast, or the subsequent archived recording, visit the "Investor Relations — Events & Presentations" section of the Tetraphase website at www.tphase.com. The webcast will be recorded and available for replay on the Tetraphase website for 30 days following the call.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase’s pipeline includes three antibiotic candidates: eravacycline, its late-stage clinical candidate, TP-271 and TP-6076. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Argot Partners Susan Kim 212-600-1902 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected]
